406,001 Shares in Repligen Corporation $RGEN Purchased by Jupiter Topco LLC

Jupiter Topco LLC purchased a new stake in shares of Repligen Corporation (NASDAQ:RGEN) in the 2nd quarter, Holdings Channel reports. The fund purchased 406,001 shares of the biotechnology company’s stock, valued at approximately $55,393,000.

A number of other hedge funds have also recently bought and sold shares of RGEN. ABS Investment Management LLC acquired a new position in shares of Repligen during the 2nd quarter worth approximately $191,016,000. Hsbc Holdings PLC bought a new stake in shares of Repligen during the 2nd quarter worth approximately $3,302,000. EFG International AG acquired a new stake in shares of Repligen in the 2nd quarter valued at approximately $5,529,000. Primecap Management Co. CA acquired a new stake in shares of Repligen in the 2nd quarter valued at approximately $44,107,000. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of Repligen in the 2nd quarter valued at approximately $259,000. 97.64% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Zacks Research upgraded shares of Repligen from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 30th. Benchmark upgraded shares of Repligen from a “hold” rating to a “buy” rating and set a $185.00 price target for the company in a research note on Tuesday, July 7th. Jefferies Financial Group reissued a “hold” rating and issued a $142.00 price objective on shares of Repligen in a research report on Tuesday, May 5th. Wells Fargo & Company boosted their price objective on shares of Repligen from $180.00 to $185.00 and gave the stock an “overweight” rating in a research note on Thursday, July 30th. Finally, HSBC dropped their target price on shares of Repligen from $170.00 to $150.00 and set a “buy” rating on the stock in a report on Wednesday, June 3rd. Three analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, Repligen has an average rating of “Buy” and an average price target of $166.43.

Repligen Stock Up 1.0%

RGEN opened at $182.03 on Friday. Repligen Corporation has a 1-year low of $100.99 and a 1-year high of $188.73. The stock’s fifty day simple moving average is $151.11 and its 200 day simple moving average is $132.79. The company has a current ratio of 9.05, a quick ratio of 7.64 and a debt-to-equity ratio of 0.26. The stock has a market cap of $10.27 billion, a PE ratio of 249.36, a price-to-earnings-growth ratio of 3.29 and a beta of 1.03.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.09. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The business had revenue of $204.13 million during the quarter, compared to the consensus estimate of $201.59 million. During the same quarter last year, the firm posted $0.26 EPS. The company’s quarterly revenue was up 11.9% on a year-over-year basis. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. As a group, research analysts expect that Repligen Corporation will post 2.06 earnings per share for the current year.

Insider Activity

In other news, CFO Jason K. Garland sold 733 shares of the firm’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $145.00, for a total transaction of $106,285.00. Following the completion of the sale, the chief financial officer owned 19,359 shares in the company, valued at approximately $2,807,055. This trade represents a 3.65% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 0.60% of the company’s stock.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.